Forxiga

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
06-02-2024
Opinber matsskýrsla Opinber matsskýrsla (PAR)
06-03-2023

Virkt innihaldsefni:

dapagliflozin propanediol monohydrate

Fáanlegur frá:

AstraZeneca AB

ATC númer:

A10BK01

INN (Alþjóðlegt nafn):

dapagliflozin

Meðferðarhópur:

Drugs used in diabetes

Lækningarsvæði:

Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic

Ábendingar:

Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.

Vörulýsing:

Revision: 29

Leyfisstaða:

Authorised

Leyfisdagur:

2012-11-11

Upplýsingar fylgiseðill

                                51
B. PACKAGE LEAFLET
52
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
FORXIGA 5 MG FILM-COATED TABLETS
FORXIGA 10 MG FILM-COATED TABLETS
dapagliflozin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Forxiga is and what it is used for
2.
What you need to know before you take Forxiga
3.
How to take Forxiga
4.
Possible side effects
5.
How to store Forxiga
6.
Contents of the pack and other information
1.
WHAT FORXIGA IS AND WHAT IT IS USED FOR
WHAT FORXIGA IS
Forxiga contains the active substance dapagliflozin. It belongs to a
group of medicines called “sodium
glucose co-transporter-2 (SGLT2) inhibitors”. They work by blocking
the SGLT2 protein in your
kidney. By blocking this protein, blood sugar (glucose), salt (sodium)
and water are removed from
your body via the urine.
WHAT FORXIGA IS USED FOR
Forxiga is used to treat:

TYPE 2 DIABETES
-
in adults and children aged 10 years and older.
-
if your type 2 diabetes cannot be controlled with diet and exercise.
-
Forxiga can be used on its own or together with other medicines to
treat diabetes.
-
It is important to continue to follow the advice on diet and exercise
given to you by your
doctor, pharmacist or nurse.

HEART FAILURE
-
in adults (aged 18 years and older) when the heart does not pump blood
as well as it
should.

CHRONIC KIDNEY DISEASE
-
in adults with reduced kidney function.
WHAT IS TYPE 2 DIABETES AND HOW DOES FORXIGA HELP?

In type 2 diabetes your body does not make enough insulin or is not
able to use the insulin i
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Forxiga 5 mg film-coated tablets
Forxiga 10 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Forxiga 5 mg film-coated tablets
Each tablet contains dapagliflozin propanediol monohydrate equivalent
to 5 mg dapagliflozin.
_Excipient with known effect_
Each 5 mg tablet contains 25 mg of lactose.
Forxiga 10 mg film-coated tablets
Each tablet contains dapagliflozin propanediol monohydrate equivalent
to 10 mg dapagliflozin.
_Excipient with known effect_
Each 10 mg tablet contains 50 mg of lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Forxiga 5 mg film-coated tablets
Yellow, biconvex, 0.7 cm diameter round, film-coated tablets with
“5” engraved on one side and
“1427” engraved on the other side.
Forxiga 10 mg film-coated tablets
Yellow, biconvex, approximately 1.1 x 0.8 cm diagonally
diamond-shaped, film-coated tablets with
“10” engraved on one side and “1428” engraved on the other
side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Type 2 diabetes mellitus
Forxiga is indicated in adults and children aged 10 years and above
for the treatment of insufficiently
controlled type 2 diabetes mellitus as an adjunct to diet and exercise
-
as monotherapy when metformin is considered inappropriate due to
intolerance.
-
in addition to other medicinal products for the treatment of type 2
diabetes.
For study results with respect to combination of therapies, effects on
glycaemic control, cardiovascular
and renal events, and the populations studied, see sections 4.4, 4.5
and 5.1.
Heart failure
Forxiga is indicated in adults for the treatment of symptomatic
chronic heart failure.
3
Chronic kidney disease
Forxiga is indicated in adults for the treatment of chronic kidney
disease.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Type 2 diabetes mellitus_
The recommended dose is 10 mg dapagliflozin once daily.
When dapagliflozin is used in combination with
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 06-02-2024
Vara einkenni Vara einkenni búlgarska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla búlgarska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 06-02-2024
Vara einkenni Vara einkenni spænska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla spænska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 06-02-2024
Vara einkenni Vara einkenni tékkneska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla tékkneska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 06-02-2024
Vara einkenni Vara einkenni danska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla danska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 06-02-2024
Vara einkenni Vara einkenni þýska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla þýska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 06-02-2024
Vara einkenni Vara einkenni eistneska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla eistneska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 06-02-2024
Vara einkenni Vara einkenni gríska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla gríska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 06-02-2024
Vara einkenni Vara einkenni franska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla franska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 06-02-2024
Vara einkenni Vara einkenni ítalska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla ítalska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 06-02-2024
Vara einkenni Vara einkenni lettneska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla lettneska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 06-02-2024
Vara einkenni Vara einkenni litháíska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla litháíska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 06-02-2024
Vara einkenni Vara einkenni ungverska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla ungverska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 06-02-2024
Vara einkenni Vara einkenni maltneska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla maltneska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 06-02-2024
Vara einkenni Vara einkenni hollenska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla hollenska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 06-02-2024
Vara einkenni Vara einkenni pólska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla pólska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 06-02-2024
Vara einkenni Vara einkenni portúgalska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla portúgalska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 06-02-2024
Vara einkenni Vara einkenni rúmenska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla rúmenska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 06-02-2024
Vara einkenni Vara einkenni slóvakíska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 06-02-2024
Vara einkenni Vara einkenni slóvenska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla slóvenska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 06-02-2024
Vara einkenni Vara einkenni finnska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla finnska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 06-02-2024
Vara einkenni Vara einkenni sænska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla sænska 10-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 06-02-2024
Vara einkenni Vara einkenni norska 06-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 06-02-2024
Vara einkenni Vara einkenni íslenska 06-02-2024
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 06-02-2024
Vara einkenni Vara einkenni króatíska 06-02-2024
Opinber matsskýrsla Opinber matsskýrsla króatíska 10-11-2021

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu